Podcasts Health Empowered Patient Podcast Developing Prodrug to Treat Rare Sleep Disorder Idiopathic Hypersomnia with Dr. Travis Mickle KemPharm

Developing Prodrug to Treat Rare Sleep Disorder Idiopathic Hypersomnia with Dr. Travis Mickle KemPharm

Published: April 20, 2022, 2:29 p.m.

Dr. Travis Mickle is the President and CEO of KemPharm, a clinical clinical-stage specialty pharmaceutical company. KemPharm is building on their successful launch of AZSTARYS for ADHD to treat rare sleep disorders like idiopathic hypersomnia as well as sleep disorders that are a symptom of diseases like Alzheimer's and Parkinson's.

Travis explains, "We focused most of our history in the CNS area on a broad base, but idiopathic hypersomnia is now a rare sleep disorder. In the past, we focused on ADHD and pain and larger patient populations. But now, I think, we're focusing more on specific needs of patients with severe, debilitating diseases."

"As an example, our lead product that just got approved last year, AZSTARYS, for ADHD, we thought, well, perhaps it would be better if that product could last longer, as well as have less abuseability."

"That prodrug now makes the basis for our KP1077 for idiopathic hypersomnia. So, you can see how one product can actually have an impact in many different areas when you make a new, improved prodrug form."

@KemPharm #SDX #SleepDisorders #CNS #ADHA #Prodrug #IdiopathicHypersomnia #AZSTARYS #RareDiseases

KemPharm.com

Download the transcript here

KemPharm